Neil Gallagher

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Waltham, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Michael LaCascia, Attorney-in-Fact for Neil Gallagher
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Neil Gallagher

Form 4 holding President, Head of R&D

Syndax Pharmaceuticals Inc

Security class
Stock Options (Right to buy)
Shares / value
110,500
Estimated value
$1,618,825
Report date
05 Feb 2025
Price
$14.65
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President, Head of R&D

Syndax Pharmaceuticals Inc

Security class
Common Stock
Shares / value
85,095
Estimated value
$1,319,313
Report date
10 Feb 2025
Price
$15.50
Ownership
Direct
Form 4 holding Director

Foghorn Therapeutics Inc.

Security class
Stock Options (Right to buy)
Shares / value
50,000
Estimated value
$208,000
Report date
01 May 2025
Price
$4.16
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Zymeworks Inc.

Security class
Stock Option (Right to Buy)
Shares / value
31,000
Estimated value
Report date
10 Dec 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Zymeworks Inc.

Security class
No securities are beneficially owned
Shares / value
0
Estimated value
Report date
02 Apr 2024
Price
Ownership
Direct

Insider Reports Filed by Neil Gallagher

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .